Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.

Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy GK, Ou SI, Stephens PJ, McPherson JD, Lara PN Jr, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB.

J Thorac Oncol. 2018 Oct;13(10):1560-1568. doi: 10.1016/j.jtho.2018.06.019. Epub 2018 Jul 5.

2.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

3.

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).

Wagner LI, Zhao F, Goss PE, Chapman JW, Shepherd LE, Whelan TJ, Mattar BI, Bufill JA, Schultz WC, LaFrancis IE, Nagargoje GG, Vemuri R, Nikcevich DA, Sledge GW, Cella D.

Breast Cancer Res Treat. 2018 Jun;169(3):537-548. doi: 10.1007/s10549-018-4713-2. Epub 2018 Feb 17.

4.

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.

Schrock AB, Li SD, Frampton GM, Suh J, Braun E, Mehra R, Buck SC, Bufill JA, Peled N, Karim NA, Hsieh KC, Doria M, Knost J, Chen R, Ou SI, Ross JS, Stephens PJ, Fishkin P, Miller VA, Ali SM, Halmos B, Liu JJ.

J Thorac Oncol. 2017 Jun;12(6):932-942. doi: 10.1016/j.jtho.2017.03.005. Epub 2017 Mar 16.

5.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA.

Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13.

6.

Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ.

Oncologist. 2012;17(1):13. doi: 10.1634/theoncologist.2011-0253. Epub 2011 Dec 30.

7.

Age-Related Disease Penetrance in a Large Medullary Thyroid Cancer Family With a Codon 609 RET Gene Mutation.

Halling KC, Bufill JA, Cotter M, Artz SA, Carpenter AB, Schaid D, Hartman-Adams H, Chang HH, Boustany MM, Fithian L, Jhiang SM, Thibodeau SN.

Mol Diagn. 1997 Dec;2(4):277-286.

PMID:
10462620
8.

Hereditary desmoid disease in a family with a germline Alu I repeat mutation of the APC gene.

Halling KC, Lazzaro CR, Honchel R, Bufill JA, Powell SM, Arndt CA, Lindor NM.

Hum Hered. 1999 Mar;49(2):97-102.

PMID:
10077730
9.

Phenotypic expression of disease in families that have mutations in the 5' region of the adenomatous polyposis coli gene.

Giardiello FM, Brensinger JD, Luce MC, Petersen GM, Cayouette MC, Krush AJ, Bacon JA, Booker SV, Bufill JA, Hamilton SR.

Ann Intern Med. 1997 Apr 1;126(7):514-9.

PMID:
9092316
10.

Colorectal cancer genetics. Closing the gap between genotype and phenotype.

Bufill JA.

Cancer. 1995 Dec 15;76(12):2389-92. No abstract available.

PMID:
8625064
11.

Intra-arterial chemotherapy for palliation of fungating breast cancer. A case report and review of the literature.

Bufill JA, Grace WR, Neff R.

Am J Clin Oncol. 1994 Apr;17(2):118-24. Review.

PMID:
7511325
12.

Relation of meat, fat, and fiber intake to the risk of colon cancer in women.

Bufill JA.

N Engl J Med. 1992 Jan 16;326(3):199; author reply 201-2. No abstract available.

PMID:
1727552
13.
14.

Yersinia enterocolitica serotype O:3 sepsis after blood transfusion.

Bufill JA, Ritch PS.

N Engl J Med. 1989 Mar 23;320(12):810. No abstract available.

PMID:
2922034
15.

Amyl nitrite-induced hemolytic anemia.

Brandes JC, Bufill JA, Pisciotta AV.

Am J Med. 1989 Feb;86(2):252-4. No abstract available.

PMID:
2563312
16.

Pityrosporum folliculitis after bone marrow transplantation. Clinical observations in five patients.

Bufill JA, Lum LG, Caya JG, Chitambar CR, Ritch PS, Anderson T, Ash RC.

Ann Intern Med. 1988 Apr;108(4):560-3.

PMID:
3279893

Supplemental Content

Loading ...
Support Center